128 related articles for article (PubMed ID: 17377924)
1. Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).
Tackenberg B; Metz A; Unger M; Schimke N; Passow S; Hoeffken H; Hoffmann GF; Müller U; Nolte D; Oertel WH; Eggert K; Möller JC
Mov Disord; 2007 Apr; 22(6):900-2. PubMed ID: 17377924
[No Abstract] [Full Text] [Related]
2. Nigrostriatal pathway dysfunction in a methanol-induced delayed dystonia-parkinsonism.
Franquet E; Salvadó-Figueres M; Lorenzo-Bosquet C; Cuberas-Borrós G; Rovira A; Castell-Conesa J; Hernandez-Vara J
Mov Disord; 2012 Sep; 27(10):1220-1. PubMed ID: 22976778
[No Abstract] [Full Text] [Related]
3. Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor-ataxia syndrome.
Healy DG; Bressman S; Dickson J; Silveira-Moriyama L; Schneider SA; Sullivan SS; Massey L; Bhatia KP; Shaw K; Bhatia KP; Bomanji J; Wood NW; Lees AJ
Mov Disord; 2009 Jun; 24(8):1245-7. PubMed ID: 19260103
[No Abstract] [Full Text] [Related]
4. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
Booij J; Berendse HW
J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
[TBL] [Abstract][Full Text] [Related]
5. TechSight. Imaging. A molecular map for neurodegeneration.
Marek K; Seibyl J
Science; 2000 Jul; 289(5478):409-11. PubMed ID: 10939953
[No Abstract] [Full Text] [Related]
6. Objective measures for the progression of Parkinson's disease.
Snow B
J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
[No Abstract] [Full Text] [Related]
7. DAT imaging in drug-induced and psychogenic parkinsonism.
Tolosa E; Coelho M; Gallardo M
Mov Disord; 2003 Oct; 18 Suppl 7():S28-33. PubMed ID: 14531043
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers.
Ceravolo R; Antonini A; Volterrani D; Rossi C; Goldwurm S; Di Maria E; Kiferle L; Bonuccelli U; Murri L
Neurology; 2005 Dec; 65(12):1971-3. PubMed ID: 16380622
[TBL] [Abstract][Full Text] [Related]
9. Parkinsonism due to ephedrone neurotoxicity: a case report.
Colosimo C; Guidi M
Eur J Neurol; 2009 Jun; 16(6):e114-5. PubMed ID: 19453409
[No Abstract] [Full Text] [Related]
10. Dopaminergic function and progression of Parkinson's disease: PET findings.
Biju G; de la Fuente-Fernández R
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S38-40. PubMed ID: 20123555
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women.
Waters CH; Takahashi H; Wilhelmsen KC; Shubin R; Snow BJ; Nygaard TG; Moskowitz CB; Fahn S; Calne DB
Neurology; 1993 Aug; 43(8):1555-8. PubMed ID: 8351010
[TBL] [Abstract][Full Text] [Related]
12. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism.
Malaguti MC; Melzi V; Di Giacopo R; Monfrini E; Di Biase E; Franco G; Borellini L; Trezzi I; Monzio Compagnoni G; Fortis P; Feraco P; Orrico D; Cucurachi L; Donner D; Rizzuti M; Ronchi D; Bonato S; Bresolin N; Corti S; Comi GP; Di Fonzo A
Parkinsonism Relat Disord; 2015 Mar; 21(3):337-9. PubMed ID: 25601130
[No Abstract] [Full Text] [Related]
13. Neuropsychological deficits associated with destruction of the right nigrostriatal pathway.
Sáez-Zea C; Escamilla-Sevilla F; Martínez-Simón J; Arnedo M; Mínguez-Castellanos A
J Int Neuropsychol Soc; 2013 Jul; 19(6):729-34. PubMed ID: 23591388
[TBL] [Abstract][Full Text] [Related]
14. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
[TBL] [Abstract][Full Text] [Related]
15. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
16. Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency.
Jeon BS; Jeong JM; Park SS; Lee MC
Adv Neurol; 1998; 78():309-17. PubMed ID: 9750927
[No Abstract] [Full Text] [Related]
17. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Cordes M; Poewe W
Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
[TBL] [Abstract][Full Text] [Related]
18. Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway.
Zijlmans J; Booij J; Valk J; Lees A; Horstink M
Mov Disord; 2002 Sep; 17(5):1086-8. PubMed ID: 12360565
[TBL] [Abstract][Full Text] [Related]
19. Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder.
Salsone M; Labate A; Quattrone A
Mov Disord; 2012 Jul; 27(8):1068-9. PubMed ID: 22605537
[No Abstract] [Full Text] [Related]
20. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
